Publication:
Potential association of plasma lysophosphatidic acid (LPA) species with cognitive impairment in abstinent alcohol use disorders outpatients

Simple item page
dc.contributor.authorGarcía-Marchena, Nuria
dc.contributor.authorPizarro, Nieves
dc.contributor.authorPavón, Francisco J.
dc.contributor.authorMartínez-Huélamo, Miriam
dc.contributor.authorFlores-López, María
dc.contributor.authorRequena-Ocaña, Nerea
dc.contributor.authorAraos, Pedro
dc.contributor.authorSilva-Peña, Daniel
dc.contributor.authorSuárez, Juan
dc.contributor.authorSantín, Luis J.
dc.contributor.authorde la Torre, Rafael
dc.contributor.authorRodríguez de Fonseca, Fernando
dc.contributor.authorSerrano, Antonia
dc.contributor.authoraffiliation[García-Marchena,N; Pavón,FJ; Flores-López,M; Requena-Ocaña,N; Araos,P; Silva-Peña,D; Suárez,J; Rodríguez de Fonseca,F; Serrano,A] Laboratorio de Medicina Regenerativa, Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Málaga, Spain. [García-Marchena,N] Institut D, Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Unidad de Adicciones-Servicio de Medicina Interna, Badalona, Spain. [Pizarro,N; Martínez-Huélamo,M; de la Torre,R] Integrative Pharmacology and Systems Neurosciences Research Group, Programa de Investigación en Neurociencias, Institut Hospital del Mar d’Investigacions Mediques (IMIM), Barcelona, Spain. [Pavón,FJ] Unidad de Gestión Clínica del Corazón, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria de Málaga, Malaga, Spain. [Pavón,FJ] Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. [Martínez-Huélamo,M] Departamento de Nutrición, Ciencias de los Alimentos y Gastronomía, Facultad de Farmacia y Ciencias de los Alimentos, Universidad de Barcelona, Barcelona, Spain. [Araos,P; Santín,LJ] Departamento de Psicobiología y Metodología de las Ciencias del Comportamiento, Instituto de Investigación Biomédica de Málaga (IBIMA), Facultad de Psicología, Universidad de Málaga (UMA), Malaga, Spain.
dc.date.accessioned2022-08-02T07:32:55Z
dc.date.available2022-08-02T07:32:55Z
dc.date.issued2020-10-13
dc.description.abstractLysophosphatidic acid (LPA) species are bioactive lipids participating in neurodevelopmental processes. The aim was to investigate whether the relevant species of LPA were associated with clinical features of alcohol addiction. A total of 55 abstinent alcohol use disorder (AUD) patients were compared with 34 age/sex/body mass index-matched controls. Concentrations of total LPA and 16:0-LPA, 18:0-LPA, 18:1-LPA, 18:2-LPA and 20:4-LPA species were quantified and correlated with neuroplasticity-associated growth factors including brain derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1) and IGF-2, and neurotrophin-3 (NT-3). AUD patients showed dysexecutive syndrome (22.4%) and memory impairment (32.6%). Total LPA, 16:0-LPA, 18:0-LPA and 18:1-LPA concentrations, were decreased in the AUD group compared to control group. Total LPA, 16:0-LPA, 18:2-LPA and 20:4-LPA concentrations were decreased in men compared to women. Frontal lobe functions correlated with plasma LPA species. Alcohol-cognitive impairments could be related with the deregulation of the LPA species, especially in 16:0-LPA, 18:1-LPA and 20:4-LPA. Concentrations of BDNF correlated with total LPA, 18:2-LPA and 20:4-LPA species. The relation between LPA species and BDNF is interesting in plasticity and neurogenesis functions, their involvement in AUD might serve as a biomarker of cognitive impairment.es_ES
dc.description.sponsorshipThe present study has been supported by the following programs and research projects: Subprograma Redes Temáticas RETICS (Red de Trastornos Adictivos RD16/0017/001 and RD12/0028/0021) funded by Instituto de Salud Carlos III (ISCIII), Ministerio de Economía y Competitividad (MINECO) and the European Regional and European Regional Development Funds/European Social Fund (ERDF/ESF); Proyectos de Investigación en Salud (PI16/01953, PI16/01698 and PI17/02026) funded by ISCIII and ERDF/ESF; Proyectos de Investigación en Drogodependencias (PND2017/043, PND2018/033, PND2018/044 and PND2019/040) funded by Delegación del Gobierno para el Plan Nacional sobre Drogas, Ministerio de Sanidad, Secretaría de Estado de Sanidad and ERDF/ESF; Proyecto de Investigación en Salud (PI-0140-2018) funded by Consejería de Salud y Bienestar Social, Junta de Andalucía and ERDF/ESF. NGM holds a “Sara Borrell” research contract (CD19/00019) funded by ISCIII and ERDF/ESF. FJP, AS and JS hold a “Miguel Servet II” research contract (CPII19/00022, CPII19/00031 and CPII17/00024, respectively) funded by ISCIII and ERDF/ESF. RTF holds a Grant (2017 SGR 138) funded by Departament d’Economia i Coneixement de la Generalitat de Catalunya (CIBEROBN), ISCIII and ERDF/ESF.es_ES
dc.description.versionYeses_ES
dc.format.extent12 p.es_ES
dc.identifier.citationGarcía-Marchena N, Pizarro N, Pavón FJ, Martínez-Huélamo M, Flores-López M, Requena-Ocaña N, et al. Potential association of plasma lysophosphatidic acid (LPA) species with cognitive impairment in abstinent alcohol use disorders outpatients. Sci Rep. 2020 Oct 13;10(1):17163es_ES
dc.identifier.doi10.1038/s41598-020-74155-0es_ES
dc.identifier.essn2045-2322
dc.identifier.pmcPMC7555527
dc.identifier.pmid33051508es_ES
dc.identifier.urihttp://hdl.handle.net/10668/3862
dc.journal.titleScientific Reports
dc.language.isoen
dc.publisherSpringer Naturees_ES
dc.relation.publisherversionhttps://www.nature.com/articles/s41598-020-74155-0es_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAlcoholismes_ES
dc.subjectPatientses_ES
dc.subjectPlasmaes_ES
dc.subjectReceptors, lysophosphatidic acides_ES
dc.subjectCognitive dysfunctiones_ES
dc.subjectAlcoholismoes_ES
dc.subjectPacienteses_ES
dc.subjectReceptores del ácido lisofosfatídicoes_ES
dc.subjectDisfunción cognitivaes_ES
dc.subject.meshMedical Subject Headings::Persons::Persons::Age Groups::Adolescentes_ES
dc.subject.meshMedical Subject Headings::Persons::Persons::Age Groups::Adultes_ES
dc.subject.meshMedical Subject Headings::Persons::Persons::Age Groups::Adult::Agedes_ES
dc.subject.meshMedical Subject Headings::Psychiatry and Psychology::Mental Disorders::Substance-Related Disorders::Alcohol-Related Disorders::Alcoholismes_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Biological Factors::Biological Markerses_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Nerve Growth Factors::Brain-Derived Neurotrophic Factores_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Alcohols::Ethanoles_ES
dc.subject.meshMedical Subject Headings::Check Tags::Femalees_ES
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Somatomedins::Insulin-Like Growth Factor Ies_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Somatomedins::Insulin-Like Growth Factor IIes_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Lipids::Membrane Lipids::Phospholipids::Glycerophosphates::Phosphatidic Acids::Lysophospholipidses_ES
dc.subject.meshMedical Subject Headings::Check Tags::Malees_ES
dc.subject.meshMedical Subject Headings::Persons::Persons::Age Groups::Adult::Middle Agedes_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Nerve Growth Factors::Neurotrophin 3es_ES
dc.subject.meshMedical Subject Headings::Persons::Persons::Patients::Outpatientses_ES
dc.subject.meshMedical Subject Headings::Anatomy::Fluids and Secretions::Body Fluids::Blood::Plasmaes_ES
dc.subject.meshMedical Subject Headings::Persons::Persons::Age Groups::Adult::Young Adultes_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, G-Protein-Coupled::Receptors, Lysophospholipid::Receptors, Lysophosphatidic Acides_ES
dc.titlePotential association of plasma lysophosphatidic acid (LPA) species with cognitive impairment in abstinent alcohol use disorders outpatientses_ES
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
GarciaMarchena_PotentialAssociation.pdf
Size:
1.59 MB
Format:
Adobe Portable Document Format
Description:
Artículo publicado
Download
No Thumbnail Available
Name:
GarciaMarchena_PotentialAssociation_MaterialSuplementario.docx
Size:
25.78 KB
Format:
Microsoft Word XML
Description:
Material suplementario
Download

Collections

SAS - Hospital Universitario Virgen de la Victoria
SAS - Hospital Regional Universitario de Málaga

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía